ATE331789T1 - Selbsterhaltender lactococcus stamm - Google Patents

Selbsterhaltender lactococcus stamm

Info

Publication number
ATE331789T1
ATE331789T1 AT02740565T AT02740565T ATE331789T1 AT E331789 T1 ATE331789 T1 AT E331789T1 AT 02740565 T AT02740565 T AT 02740565T AT 02740565 T AT02740565 T AT 02740565T AT E331789 T1 ATE331789 T1 AT E331789T1
Authority
AT
Austria
Prior art keywords
self
supporting
lactococcus
survive
lactococcus strain
Prior art date
Application number
AT02740565T
Other languages
English (en)
Inventor
Lothar Steidler
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE331789T1 publication Critical patent/ATE331789T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01045—Thymidylate synthase (2.1.1.45)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT02740565T 2001-05-03 2002-05-03 Selbsterhaltender lactococcus stamm ATE331789T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201631 2001-05-03
EP01204785 2001-12-07

Publications (1)

Publication Number Publication Date
ATE331789T1 true ATE331789T1 (de) 2006-07-15

Family

ID=26076897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02740565T ATE331789T1 (de) 2001-05-03 2002-05-03 Selbsterhaltender lactococcus stamm

Country Status (9)

Country Link
EP (1) EP1383897B1 (de)
JP (2) JP4347575B2 (de)
AT (1) ATE331789T1 (de)
AU (1) AU2002314040B2 (de)
CA (1) CA2446776C (de)
DE (1) DE60212825T2 (de)
DK (1) DK1383897T3 (de)
ES (1) ES2266515T3 (de)
WO (1) WO2002090551A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2004001020A2 (en) 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and means to promote gut absorption
WO2004056850A2 (en) * 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
JP4589618B2 (ja) * 2003-11-28 2010-12-01 独立行政法人農業生物資源研究所 免疫調節性機能を誘導する乳酸菌類とその成分
US9200249B2 (en) 2004-08-20 2015-12-01 Actogenix N.V. Method to improve Lactococcus preservation
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
EP2097452A1 (de) * 2006-12-14 2009-09-09 Actogenix N.V. Verabreichung von bindungsmolekülen zur induktion einer immunomodulation
ES2595729T3 (es) 2007-01-12 2017-01-03 Intrexon Actobiotics Nv Promotores de Lactococcus y usos de los mismos
CN103933563B (zh) 2007-01-25 2016-09-28 英特瑞克斯顿阿克图比奥帝克斯有限公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
CA2738781C (en) * 2008-09-29 2020-06-09 Intrexon Actobiotics Nv Reduced colonization of microbes at the mucosa
ES2676877T3 (es) 2011-06-01 2018-07-25 Intrexon Actobiotics Nv Sistema de expresión policistrónica para bacterias
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
EP3265105A1 (de) * 2015-03-02 2018-01-10 Synlogic, Inc. Manipulierte bakterien zur behandlung von krankheiten, die von reduzierter darmentzündung und/oder verstärkter darmschleimhautbarriere profitieren
CN106148254B (zh) * 2015-03-26 2019-11-12 南京华贞生物医药科技有限公司 一种用于减肥降脂的转化体及其构建方法与应用
IL296538A (en) 2015-05-13 2022-11-01 Synlogic Operating Co Inc A genetically engineered bacterium to lower hyperphenylamine
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
PL3377518T3 (pl) 2015-11-16 2022-09-26 Synlogic Operating Company, Inc. Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii
EP3402499B1 (de) 2016-01-14 2021-07-21 Intrexon Actobiotics NV Zusammensetzungen und verfahren zur behandlung von typ-1-diabetes
AU2017319707B2 (en) 2016-09-02 2023-11-09 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
WO2018051223A1 (en) 2016-09-13 2018-03-22 Intrexon Actobiotics N.V. Mucoadhesive microorganism
AU2018290278B2 (en) 2017-06-21 2022-12-15 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
WO2020075171A1 (en) 2018-10-11 2020-04-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Bacteria expressing single chain antibodies against toll-like receptors
CN114761028A (zh) 2019-09-27 2022-07-15 英特瑞克斯顿阿克图比奥帝克斯有限公司 乳糜泻的治疗
AU2021240078A1 (en) 2020-03-20 2022-09-01 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4231764A1 (de) * 1992-09-23 1994-03-24 Inst Pflanzengenetik & Kultur Verfahren zur chromosomalen Integration eines Produkt-Gens

Also Published As

Publication number Publication date
DK1383897T3 (da) 2006-10-30
CA2446776C (en) 2011-07-12
DE60212825T2 (de) 2007-01-11
JP2009060913A (ja) 2009-03-26
EP1383897B1 (de) 2006-06-28
WO2002090551A2 (en) 2002-11-14
DE60212825D1 (de) 2006-08-10
CA2446776A1 (en) 2002-11-14
JP2004533246A (ja) 2004-11-04
JP4347575B2 (ja) 2009-10-21
ES2266515T3 (es) 2007-03-01
EP1383897A2 (de) 2004-01-28
AU2002314040B2 (en) 2007-06-28
WO2002090551A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
ATE331789T1 (de) Selbsterhaltender lactococcus stamm
DE602005022740D1 (de) Amplifikationsblocker umfassend interkalierende nukleinsäuren (ina) enthaltend interkalierende pseudonukleotide (ipn)
WO2004046346A3 (en) Self-containing lactobacillus strain
PL1668001T3 (pl) Podstawione heteroarylobenzofuranowe kwasy
DE50210271D1 (de) Amphotere liposomen und verwendung dieser
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
ATE286060T1 (de) Präpolymere (meth)acrylate mit polycyclischen oder aromatischen segmenten
HRP20050705B1 (hr) Ekspresijski vektor koji sadrži promotor mcmv ie2
SE0004420D0 (sv) Förstärkare
DK1562444T3 (da) Fremgangsmåde til formindskelse af acrylamidindholdet i varmebehandlede levnedsmidler
ATE341606T1 (de) Natriumpercarbonatpartikel mit verbesserter lagerstabilit t
AU2003218099A1 (en) Modulation of the immune response through the manipulation of arginine levels
AU2003214098A1 (en) Ceramic colorants in the form of nanometric suspensions
ATE363540T1 (de) Enzymatische herstellung von (meth)acrylsäureestern
TW200708929A (en) Opposite-phase scheme for peak current reduction
ATE288922T1 (de) Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
BR0101695A (pt) Grão abrasivo melhorado
CL2009000674A1 (es) Cepa de myxococcus virescens st200611 (dsm 15898) y procedimiento para preparar compuestos derivados de bengamida mediante fermentacion con dichos microorganismos.
AU2003206926A1 (en) Cultivation method for micro-organisms and bioreactor
DE60204778D1 (de) Zweidimensionale pyramidenfilterarchitektur
DK1395662T3 (da) Fremgangsmåde til fremstilling af D-pantothensyre og/eller salte deraf
WO2001068846A3 (en) Transcription activator of the cited family
ATE288148T1 (de) Zweidimensionale pyramidenfilterarchitektur
ATE402998T1 (de) D-hydantoinase aus ochrobactrum anthropi
AU2003294162A1 (en) Inter-application control to improve the performance of playback of stored interactive-tv applications

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1383897

Country of ref document: EP